ZNF830 and non-small cell lung carcinoma: In a xenograft model of non-small cell lung cancer, depletion of ZNF830 was able to dramatically inhibit tumor growth in combination with treatment with the PARP inhibitor, Olaparib, although it remains to be seen whether targeting ZNF830 in established tumors will have similar effects (Chen et al., 2018).